NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Forecast & News

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings results on Monday, November, 4th. The company reported $1.46 earnings per share for the quarter, missing analysts' consensus estimates of $1.72 by $0.26. The company earned $160.85 million during the quarter, compared to analysts' expectations of $168.60 million. Taro Pharmaceutical Industries had a net margin of 40.43% and a return on equity of 14.13%. View Taro Pharmaceutical Industries' Earnings History.

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Taro Pharmaceutical Industries.

1 Wall Street analysts have issued 12-month price targets for Taro Pharmaceutical Industries' shares. Their forecasts range from $110.00 to $110.00. On average, they anticipate Taro Pharmaceutical Industries' share price to reach $110.00 in the next year. This suggests a possible upside of 18.0% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

Media stories about TARO stock have trended extremely negative on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Taro Pharmaceutical Industries.

Taro Pharmaceutical Industries saw a increase in short interest in November. As of November 29th, there was short interest totalling 297,400 shares, an increase of 6.5% from the November 14th total of 279,200 shares. Based on an average daily trading volume, of 79,500 shares, the short-interest ratio is currently 3.7 days. Currently, 3.3% of the shares of the company are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Some companies that are related to Taro Pharmaceutical Industries include Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Amarin (AMRN) and Sarepta Therapeutics (SRPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), Supernus Pharmaceuticals (SUPN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (nbix) and Southwest Airlines (LUV).

Taro Pharmaceutical Industries' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include CLARET ASSET MANAGEMENT Corp (0.22%), Millennium Management LLC (0.21%), California Public Employees Retirement System (0.11%), Systematic Financial Management LP (0.02%) and Squarepoint Ops LLC (0.01%).

TARO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, CLARET ASSET MANAGEMENT Corp and Systematic Financial Management LP.

TARO stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Squarepoint Ops LLC.

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TARO stock can currently be purchased for approximately $93.19.

Taro Pharmaceutical Industries has a market capitalization of $3.59 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries.

The official website for Taro Pharmaceutical Industries is http://www.taro.com/.

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]